ArticleNature cancer2020
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.Cell · 2021Pooled it
- Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.Nature communications · 2022Trial
- Article
- Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer.NPJ precision oncology · 2026Article
- Single-cell differential abundance detection: A new angle on dissecting tumor heterogeneity.World journal of clinical oncology · 2026Review
- Reversing T cell dysfunction in a novelFrontiers in immunology · 2026Article
- Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients.Oxford open immunology · 2026Article
- HROB is a novel prognostic biomarker correlated with immune cell infiltration and tumor progression in lung adenocarcinoma.World journal of surgical oncology · 2025Article
- Early cancer detection via multi-omics cfDNA fragmentation using early-late fusion neural network with sample-modality evaluation.Briefings in bioinformatics · 2025Article
- The diversity of CD8Nature reviews. Immunology · 2025Review
- Article
- Immune regeneration: implications for cancer immunotherapy and beyond.The Journal of clinical investigation · 2025Review
- Construction and validation of a prognostic and therapeutic cuproptosis- and immune-related gene signature in hepatocellular carcinoma.Translational cancer research · 2024Article
- Deep cell phenotyping and spatial analysis of multiplexed imaging with TRACERx-PHLEX.Nature communications · 2024Article
- Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer.Cancer discovery · 2024Article
- Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.Oncoimmunology · 2024Article
- Stem-like exhausted and memory CD8Nature reviews. Cancer · 2023Review
- Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer.Clinical and translational medicine · 2023Article
- Article
- Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 8 countries.
Ehsan Ghorani *Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-5373-5762
James L Reading *Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. j.reading@ucl.ac.uk.ORCID http://orcid.org/0000-0001-5381-978X
Jake Y HenryCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Marc Robert de MassyCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-3048-1680
Rachel RosenthalCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Virginia TuratiDepartment of Cancer Biology, University College London Cancer Institute, London, UK.
Kroopa JoshiCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Andrew J S FurnessDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Assma Ben AissaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Sunil Kumar SainiDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.ORCID http://orcid.org/0000-0003-3382-9432
Sofie RamskovDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.ORCID http://orcid.org/0000-0001-9413-8673
Andrew GeorgiouCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Mariana Werner SunderlandCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Yien Ning Sophia WongCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Maria Vila De MuchaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
William DayCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Felipe Galvez-CancinoCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-8417-1891
Pablo D BeckerCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Imran UddinDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0003-0736-3149
Theres OakesDivision of Infection and Immunity, University College London, London, UK.
Mazlina IsmailDivision of Infection and Immunity, University College London, London, UK.
Tahel RonelDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-9513-9181
Annemarie WoolstonDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-8932-2895
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolai J BirkbakCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Gareth A WilsonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Kevin LitchfieldCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Lucia CondeBill Lyons Informatics Centre, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-5180-543X
José Afonso Guerra-AssunçãoBill Lyons Informatics Centre, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6593-403X
Kevin BligheBill Lyons Informatics Centre, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6322-6571
Dhruva BiswasCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9141-5188
Roberto SalgadoDepartment of Pathology, GZA-ZNA, Antwerp, Belgium.
Tom LundDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
David A MooreDepartment of Pathology, University College London Cancer Institute, London, UK.
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sherene LoiDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-6137-9171
Yuxin SunDivision of Infection and Immunity, University College London, London, UK.
Yinyin YuanDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Khalid AbdulJabbarDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Samra TurajilicDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Javier HerreroBill Lyons Informatics Centre, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-7313-717X
Tariq EnverDepartment of Cancer Biology, University College London Cancer Institute, London, UK.
Sine R HadrupDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.ORCID http://orcid.org/0000-0002-5937-4344
Allan HackshawCancer Research UK and University College London Cancer Trials Centre, London, UK.
Karl S PeggsCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Benny ChainDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-7417-3970
TRACERx Consortium
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Sergio A QuezadaCancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9763-1700
Cancer Research UK · GBLondon Cancer · GBThe Francis Crick Institute · GBRoyal London Hospital · GBRoyal Brompton & Harefield NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBSheffield Teaching Hospitals NHS Foundation Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Leicester · GBAberdeen Royal Infirmary · GBUniversity College London · GBCancer Research UK Manchester CentreUniversity Hospitals of Leicester NHS Trust · GBBarts Health NHS Trust · GBCardiff and Vale University Health Board · GBGolden Jubilee National Hospital · GBRoyal Marsden NHS Foundation Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GBPrincess Alexandra Hospital NHS Trust · GBUniversity of Liverpool · GB
Funding
Cancer Research UK 17786Cancer Research UK 20466Cancer Research UK 20764Cancer Research UK 21999Cancer Research UK 22246Cancer Research UK 24314Cancer Research UK 24956Cancer Research UK 25223Cancer Research UK 30025Cancer Research UK 30194Cancer Research UK A20465Cancer Research UK A22246European Research Council 617844Medical Research Council FC001169Medical Research Council MR/M009033/1Medical Research Council MR/P014712/1Medical Research Council MR/P014712/2Wellcome Trust 211179/Z/18/ZWellcome Trust FC001169Wellcome Trust FC001202
Abstract
Tumour mutational burden (TMB) predicts immunotherapy outcome in non-small cell lung cancer (NSCLC), consistent with immune recognition of tumour neoantigens. However, persistent antigen exposure is detrimental for T cell function. How TMB affects CD4 and CD8 T cell differentiation in untreated tumours, and whether this affects patient outcomes is unknown. Here we paired high-dimensional flow cytometry, exome, single-cell and bulk RNA sequencing from patients with resected, untreated NSCLC to examine these relationships. TMB was associated with compartment-wide T cell differentiation skewing, characterized by loss of TCF7-expressing progenitor-like CD4 T cells, and an increased abundance of dysfunctional CD8 and CD4 T cell subsets, with significant phenotypic and transcriptional similarity to neoantigen-reactive CD8 T cells. A gene signature of redistribution from progenitor-like to dysfunctional states associated with poor survival in lung and other cancer cohorts. Single-cell characterization of these populations informs potential strategies for therapeutic manipulation in NSCLC.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenBiomarkers, TumorCell DifferentiationHumansMutationB7-H1 AntigenBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.